JPMorgan on Protagonist Therapeutics (PTGX) Following Earlier Data: 'we believe PTGX’s current valuation is attractively positioned'
Tweet Send to a Friend
JPMorgan analyst Brian Cheng reiterated an Overweight rating and $36.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
